End-of-treatment overall response rate
| Patients, n (%) . | G-FC (n = 21) . | G-B (n = 20) . |
|---|---|---|
| ORR (CR + CRi + PR) | 13 (62) | 18 (90) |
| CR | 2 (10) | 4 (20) |
| CRi | 3 (14) | 5 (25) |
| PR | 8 (38) | 9 (45) |
| SD | 4 (19) | 0 |
| PD | 0 | 0 |
| Not evaluable* | 1 (5) | 1 (5) |
| Missing† | 3 (14) | 1 (5) |
| Patients, n (%) . | G-FC (n = 21) . | G-B (n = 20) . |
|---|---|---|
| ORR (CR + CRi + PR) | 13 (62) | 18 (90) |
| CR | 2 (10) | 4 (20) |
| CRi | 3 (14) | 5 (25) |
| PR | 8 (38) | 9 (45) |
| SD | 4 (19) | 0 |
| PD | 0 | 0 |
| Not evaluable* | 1 (5) | 1 (5) |
| Missing† | 3 (14) | 1 (5) |
PD, progressive disease; PR, partial response; SD, stable disease.
Not evaluable. G-FC (n = 1) and G-B (n = 1): end-of-treatment CT not evaluable.
Missing. G-FC: response assessed too early (n = 1); early treatment discontinuation due to adverse event (n = 2). G-B: response assessed too early (n = 1).